DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nhcvqx/ovarian_cancer) has announced the addition of the "Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Survival and Targeted Therapies" report to their offering.
Population Growth and Inflation to Drive Market
Global Ovarian Cancer Therapeutics in Major Developed Markets to 2020 has identified and analyzed 10 promising late-stage pipeline drugs . However, of these 10, only Telik's Telcyta has been shown to improve median patient Overall Survival (OS); however, questions raised over the validity of the data mean that the drug is not expected to be approved within the forecast period of 2013-2020. Further Phase III trials of the drug are required, for which Telcyta is currently seeking corporate partners. Most of the late-stage drugs provide no clinical benefit to patients, with the best responses being mild to moderate improvements in Progression-Free Survival (PFS) in comparison with standard-of care treatment.
In the projected scenario, those drugs that have been shown to provide an improvement in PFS will be approved in the EU, Canada and Japan. These are Vynfinit, olaparib and Trebananib. This is in line with the most recent drug approvals in these markets: Avastin and Yondelis, which were approved on the basis of improved PFS. However, the expected high cost of these drugs and their minimal clinical benefit, are expected to create a negative opinion of them among healthcare professionals and regulatory bodies in these three geographies, limiting their prescription volumes.
In the US, the improvements in PFS observed with Yondelis and Avastin were not sufficient for either drug to be granted approval in the US. However, despite its refusal, Avastin is approved for other indications within oncology, with evidence that the drug is prescribed off-label for the treatment of Ovarian Cancer (OC) in the US, contributing significantly to the current market (Burger, 2007). The inflation of Avastin, which costs up to $100,000 for a course of treatment, is expected to be a major contributor to market growth in the US and globally. Given the similar lack of OS benefit with current late-stage pipeline drugs, it is unlikely the aforementioned late-stage pipeline drugs will be approved in the US within the forecast period.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Marketed Products
- Carboplatin
- Paclitaxel
- Gemcitabine
- Topotecan
- Pegylated Liposomal Doxorubicin
- Yondelis
- Avastin
4 Product Pipeline
5 Late-Stage Drugs in Developmental Pipeline
- Niraparib
- Olaparib
- Abagovomab
- Vargatef
- Trebananib
- Farletuzumab
- Vynfinit
- Telcyta
- Karenitecin
6 Market Forecast
7 Drivers and Barriers
- High Number of Candidates in Drug Development
- High Unmet Clinical Need
- Incentives for Orphan Drug Development
- Potential Changes to Clinical Trial Design
- Decreasing Incidence Rates
- Lack of Cell Lines
- High Heterogeneity of the Disease
- High Cost of Novel Drugs
8 Deals
- Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338
- PharmaMar Enters into Licensing Agreement with Janssen for Yondelis
- Hana Enters into Licensing Agreement with Tekmira
- AstraZeneca Enters into Licensing Agreement with Merck for MK-1775
- Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug
- Oasmia Enters into Licensing Agreement with Medison for Paclical
- Orion Enters into Agreement with Oasmia
- Ohio University Enters into Licensing Agreement with Phosplatin
- Genta Enters into Licensing Agreement with Daiichi Sankyo
- Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research
- NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300
- Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug
- Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre
- Almac Discovery Enters into an Agreement with Queen's University Belfast for Drug Discovery
9 Appendix
For more information visit http://www.researchandmarkets.com/research/nhcvqx/ovarian_cancer
